TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07408908: A Single-Center, Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled, Phase Ia Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants.

Sponsor: Xiamen Amoytop Biotech Co., Ltd. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 48 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,507,200

Rescue Site Savings

+$4,950,060

Unlock Full NCT07408908 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07408908 Rescue Dossier →